The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.
 
Quincy S. Chu
Honoraria - Abbvie; Amgen; Anheart Therapeutics; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Esperas Pharma; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Merck; Novartis; Ocellaris Pharma; Pfizer; Roche; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Anheart Therapeutics; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Esperas Pharma; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Merck; Novartis; Ocellaris Pharma; Pfizer; Roche; Takeda
 
Maria Carmela Piccirillo
Honoraria - Astellas Pharma; AstraZeneca
Research Funding - AstraZeneca (Inst); Roche (Inst)
 
Laurent Greillier
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Novartis; Roche; Takeda
Travel, Accommodations, Expenses - AstraZeneca; BMS; MSD; Pfizer; Roche
 
Federica Grosso
Honoraria - Boehringer Ingelheim; Bristol Meyer Squibb; MSD Oncology; Novartis; Novocure; PharmaMar; Pierre Fabre
Consulting or Advisory Role - Bristol Meyer Squibb; MSD Oncology; Novartis; Novocure; PharmaMar; Pierre Fabre
Speakers' Bureau - Novocure
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol Meyer Squibb; Novartis; novocure; PharmaMar
 
Giuseppe Lo Russo
Consulting or Advisory Role - Amgen (Inst); AstraZeneca/MedImmune; Bristol-Myers Squibb/Medarex; GlaxoSmithKline; italfarmaco; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda (Inst)
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb/Medarex (Inst); Celgene (Inst); GlaxoSmithKline (Inst); MSD Oncology; MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS; MSD; Roche
 
Marie Florescu
Honoraria - AstraZeneca; Bristol-Myers Squibb/Medarex; EMD Serono; Jazz Pharmaceuticals; Roche Canada
Consulting or Advisory Role - AstraZeneca; Jazz Pharmaceuticals; Roche/Genentech
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb/Medarex; Bristol-Myers Squibb/Medarex
 
Manlio Mencoboni
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca (Inst); Janssen Oncology (Inst); Mirati Therapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Novartis; Pfizer; Roche
 
Penelope Ann Bradbury
Consulting or Advisory Role - Mirati Therapeutics
(OPTIONAL) Uncompensated Relationships - Abbvie; Bristol-Myers Squibb
 
Alessandro Morabito
Consulting or Advisory Role - Boehringer Ingelheim; MSD; Takeda
Speakers' Bureau - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Lilly; MSD; Novartis; Roche
 
Fabiana Letizia Cecere
Consulting or Advisory Role - Amgen; AstraZeneca; Novartis; Roche; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb/Sanofi (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Takeda
 
Sara Delfanti
Speakers' Bureau - Bristol Myers Squibb Foundation; Pierre Fabre
Travel, Accommodations, Expenses - Bristol Myers Squibb Foundation; Novartis; Pierre Fabre
 
Arnaud Scherpereel
No Relationships to Disclose
 
Myriam Locatelli-Sanchez
No Relationships to Disclose
 
Gerard Zalcman
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Da Volterra; Inventiva Pharma; Lilly; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Da Volterra (Inst); Inventiva Pharma (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); ROCHE (Inst); ROCHE (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Lilly; Pfizer; Pfizer; Roche
 
David E Dawe
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca; Jazz Pharmaceuticals; Merck; Novartis; Pfizer
Research Funding - AstraZeneca (Inst)
 
Joana Sederias
No Relationships to Disclose
 
Scott A. Laurie
Honoraria - AstraZeneca; Boehringer Ingelheim; Pfizer
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Other Relationship - Pfizer
 
Christopher W. Lee
No Relationships to Disclose
 
Wei Tu
No Relationships to Disclose
 
Lesley Seymour
Stock and Other Ownership Interests - AstraZeneca
Research Funding - AstraZeneca (Inst); Bayer (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Repare Therapeutics (Inst)